• Article highlight
  • Article tables
  • Article images

Article History

Received : 01-02-2024

Accepted : 06-02-2024



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 378

PDF Downloaded: 164


Get Permission Augustus, Ali, Beharry, Armorer, and Lousaing: Management of a Giant Cell tumors with megaprosthesis in a resource-limited setting


Introduction

GCT of Bone was first described in 1818 by Cooper and Travers.1 Its local aggression was highlighted by Nelaton and its malignant potential by Virchow.2 It is characterized histologically by large multi-nucleated osteoclast-like giant cells, with a background of mononuclear spindle-like stromal cells that exhibit osteoclastic activity.3, 1 GCTs account for 5% of primary bone neoplasms and 20% of all primary bone tumours.4 Despite being described as benign GCTs are locally aggressive, with breach of the cortex or soft tissue expansion; and have a high recurrence rate after surgical resection.1

They predominantly occur for young adults aged 20-40 years. GCT rarely present in immature skeletons.3, 5 These tumours commonly occur in long bones,1 they have a predilection for the meta-epiphyseal regions of long bones such as in our case;50-60% occur around the knee.1 Juxta-articular tumour management is focused on clearance and reconstruction.

The typical clinical presentation is the complaint of pain due to bone resorption; localized swelling of the bone due to lysis and progression; limited range of motion secondary to their juxta-articular position; their expansile progression can lead to pathological fractures and soft tissue involvement.3 Although they are rarely lethal, they can lead to substantial disturbance of local bony architecture that can be particularly troublesome in peri-articular locations.6 Eighty percent of these cases have a benign course, 10-50% may recur and 10% may undergo malignant transformation; 1-4% may have pulmonary metastases despite their benign histology.7, 8

Delays during these patients' management can lead to detrimental outcomes. The high recurrence rate and metastatic potential warrants these cases to be closely followed up after the index procedure.

The surgical treatment is guided by the Campanacci Classification System. Other factors that are taken into consideration is the patient’s age, their previous functional status, the anatomical location of the GCT. Surgical options to be considered are intralesional curettage with bone graft +/- adjuvant therapy, wide resection +/- bone graft/ polymethyl methacrylate (PMMA)/ internal fixation/endoprosthesis, resection arthrodesis.6, 9 Wide excision is recommended once the cortex has been breached with or without soft tissue involvement.9 Early stages can be managed by intralesional curettage +/-bone grafting. Adjuvant measures such as the use of phenol, liquid nitrogen, alcohol, and peroxide can be used to decrease the likelihood of recurrence to 6-25%.10 Denosumab, a monoclonal antibody targeting RANK ligand, can be used as neoadjuvant therapy.1, 11 The challenge in choosing the treatment is complicated by the inability of the radiological and histological appearance to indicate the biological behaviour of these tumours.6

Endoprosthetic arthroplasty for Campanacci stage III achieves excellent functional and oncological outcomes. Megaprosthesis have a limited longevity due to mechanical failure. This limitation needs to be taken into consideration especially when being utilized in the younger population. Megaprosthesis facilitates improves functional outcomes as assessed by the Musculoskeletal Tumor Society Score (MSTS). The improvements made in surgical technique along with the advances in biomedical engineering over the last three decades have improved the longevity of these endoprostheses by 20-80%.6

Case Presentation

A 32-year-old male presented to the Orthopaedics Outpatient Clinic with a one-year history of atraumatic knee pain and swelling. A radiographic examination showed a lytic lesion of the right distal femur. The Magnetic Resonance Imaging (MRI) showed a well-defined, eccentric, expansile, lobulated lesion at the right lateral epi-metaphyseal region of the distal femur (63mm AP x 85 mm CC x 50 mm TR). The cortex was noted to be thinning and breached, perilesional edema was also noted.

An incisional biopsy was done, which showed a GCT of the bone. The lesion was classified as Grade III according to the Campanacci classification. He subsequently had an intra-lesional curettage and reconstructed with an autologous cancellous graft.

Figure 1

Photomicrograph (Hematoxylin-Eosin Stain) showsa background of mononuclear stromal cells and multinucleated giant cells(arrows).

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/c6ec594b-7bb7-4dba-83da-118c513a65fc-uimage.png

Figure 2

Photomicrograph shows a giant cell tumor with focal necrosis

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/5b0d9eb5-8646-4b85-b164-6ce7372f9b30-uimage.png

Thirty days after his index surgery the patient was noted to have a draining sinus and subsequently had a débridement and curettage, the bone defect was filled with antibiotic-embedded cement. A clinical and radiographic follow-up was done at one, three, six, and twelve months post-operatively to confirm bone consolidation and to assess for tumour recurrence.

At the twelve-month review, the patient reported a 3-month history of right thigh pain and chills. A repeat MRI was done, which noted a recurrence of the GCT with aggressive features. This recurrent lesion was noted to extend into subarticular bone, with no evidence of extension into the joint space; there was an associated soft tissue component extending into the adjacent vastus lateralis muscle.

The patient underwent a wide resection and reconstruction with a customized mega prosthesis. An extended anterior incision followed by a mid-vastus approach provided exposure to the knee. The dissection was done superficially to the tumour through the biopsy site. The dissection continued to the joint line and the knee was disarticulated by incising the anterior capsule, both cruciate ligaments, the meniscocapsular attachments as well as the collaterals around the posterior capsule. The proximal dissection was done to achieve 5 cm clearance, and the femur was osteotomized. The dissection continued distally maintaining proximity to the tumour posteriorly and meeting at the inferior dissection at the joint line posteriorly. The tumour was excised En bloc with the sinus tract as illustrated in Figure 6c. The popliteal fossa was assessed by the vascular surgeon. No tourniquet was utilized during this procedure. The Zimmer Biomet Orthopaedic Salvage System was inserted, this custom-made endoprosthesis was based on preoperative planning and measurements. The proximal tibia was prepared then the proximal femoral cavity was prepared. The trial components were assembled and offered to best fit. The knee was cycled, the area prepared, and the mega prosthesis cemented in situ. The incision was then closed in layers over a redivac drain.

R0 resection was achieved, and the patient reports a Musculoskeletal Tumor Society score (MSTS) of 19.12

Figure 3

Preoperative photograph of right knee illustrating mass and diffuse swelling

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/3a7a042b-51ea-4de8-b868-dd9e29d17cee-uimage.png

Figure 4

Recurrent GCT; (A): Anteroposterior Radiograph of the right knee shows an expansile lyticlesion of the lateral femoral condyle that extends into subchondral bone, destruction of the lateral cortex and an associated soft tissue mass; B): Lateral Radiograph of the right knee shows the extension of lesion into the soft tissues

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/0cd8141e-9f7b-4e97-9364-de8ac01985f4-uimage.png

Figure 5

Photograph shows customized modular endoprosthesis

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/bef94bf5-217c-4fd3-9450-50d520dec078-uimage.png

Figure 6

Intraoperative images: A): Megaprosthesis placement; B): Megaprosethsis placement; C): Resected tumour and sinus tract

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/ff04fe2c-d34e-410e-9c0b-0d3c79ceab91-uimage.png

Figure 7

A): Post-operative photograph illustrating alignment; B): Post-operative long limb length radiographs with mega prosthesis in situ

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/362dd74d-eb88-4b27-83dd-5a3c4e2aff20/image/3ebdcb9f-e095-49c8-9535-d487ad43a386-uimage.png

Discussion

The management of GCTs is challenging as their histological and radiological findings fail to reflect their biological behaviour.6 Aggressive features such as a wide zone of transition, thinning of the cortex, expansile remodelling, associated pathological fractures, and soft tissue masses may be noted on radiological investigation.

The gold standard treatment is surgical resection, aiming to attain oncological clearance while maintaining structural integrity.6, 3, 13 Depending on the extent of the osseous defect, limb-salvage surgery can be modality of choice and amputations can be avoided. En bloc resection and reconstruction almost completely eliminates the possibility of recurrence.14

Resection of juxta-articular malignant bone tumors can present challenges with reconstruction and preservation of functional ability. Reconstruction can be done with the use of biological and non-biological techniques. The modular mega prosthesis is the most frequently non-biologic reconstructive surgery for tumour resections that result in a large bone defect. Adjuvant therapies can aid in treatment in the control of local recurrence. Denosumab has recently been used as neoadjuvant chemotherapy in the treatment of GCT of bone.1

Megaprosthetic reconstruction is a viable option for Campanacci Stage III GCT. As this has comparable oncological results to amputations. This prosthesis affords the patients an improved quality of life as they are able to weight bear early and have a shorter rehabilitation course post-operatively.13 In this case report, the joint was preserved by the placement of a customized mega prosthesis. The custom-made mega-prosthesis arthroplasty was effective and accomplished the desired functional results in this case. This reconstructive procedure was chosen based on durability, oncological prognosis, anatomy, and the ability to restore the function of the limb, as well as the needs of the patient.

The advantages of immediate restoration of weight bearing, maintenance of joint stability, early return to activities of daily living, early mobility, cost-effectiveness, and comparatively low rate of recurrence make this treatment option the most viable.6

However, it is not without its complications which can be classified as mechanical and non-mechanical. Fewer mechanical complications have occurred as technique and implant design have improved; prosthetic failure occurs when more than 40% of bone has been resected. Non-mechanical such as aseptic loosening, implant failure, and periprosthetic fracture. There is a concern with using this option in young patients because of the longevity of the prosthesis. The 5 and 10-year survivals are 76% and 66% respectively. This is considered to be a favourable outcome for such complex surgical procedures.15 Prosthetic failure most commonly occurs at 48-72 months postoperatively.16 Long-term follow-up is required for these patients.

The high cost of these megaprosthesis is quite exorbitant. This can lead to delays in management, as it did in this case. Mega prostheses are not locally manufactured and needed to be imported. This custom mega prosthesis was manufactured using the dimensions that were assessed on radiographic investigations. The most common complications affecting the survival of these prostheses were aseptic loosening and infection, thus tailoring of the prosthesis must be done meticulously.

The funds for this case were provided by the Government of Trinidad and Tobago during the pandemic novel Covid-19 virus. The health care system of Trinidad and Tobago follows the Beveridge Model. This provides free health care to all citizens as most medical facilities are financed by the government.

The Covid 19 pandemic adversely affected healthcare across all medical sub-specialities- Trauma and Orthopaedics was no exception to this.17 This singular case was delayed due to resource prioritization during the pandemic. These issues included but were not limited to: the loss of elective operation time, reduction of funds for implants and prosthesis, the re-distribution of staff. These factors contributed to the delays in the management of urgent elective orthopaedic cases.18, 19

Despite these challenges, the patient had a successful oncological and functional outcome, with no recurrence after his 12-month review. These patients risk prosthetic complications as well as bone or soft tissue recurrence and face the risk of revision or amputation. They must be counselled extensively on these complications and have close follow-ups with clinical and radiological examinations. Follow-up radiographs are assessed for bone resorption, and bone or soft tissue mass with expansile destruction.20

Conclusion

GCT management is complex and requires a multi-faceted approach. This case report highlights the surgical management of a juxta-articular GCT with a custom mega-prosthesis. The custom mega-prosthesis has become the first-line choice of treatment for aggressive GCTs. It is a technically superior reconstructive modality with notable advantages that outweigh the limitations. The COVID-19 pandemic adversely affected.

Despite the logistic challenges associated with the COVID-19 pandemic a favourable outcome was achieved for this case, paving the way for future management of these cases in a resource-limited setting.

Source of Funding

None.

Conflict of Interest

None.

References

1 

CJ Chakarun DM Forrester CJ Gottsegen DB Patel EA White GR Matcuk Giant cell tumor of bone: review, mimics, and new developments in treatmentRadiographics2013331197211

2 

D Vanni A Pantalone E Andreoli P Caldora V Salini Giant cell tumor of the distal ulna: a case reportJ Med Case Rep20126143

3 

RW Cowan G Singh Giant cell tumor of bone: a basic science perspectiveBone201352123846

4 

AA Macwan SN Nanda D Mishra S Tuteja B Sandeep A giant cell tumor of the distal femur managed by excision and knee arthrodesis using a custom made long intramedullary interlocking nail: a case report and review of the literatureCureus2021135e14810

5 

A Sobti P Agrawal S Agarwala M Agarwal Giant Cell Tumor of Bone - An OverviewArch Bone Jt Surg20164129

6 

MV Natarajan R Prabhakar SM Mohamed RA Shashidhar Management of juxta-articular giant cell tumors around the knee by custom mega prosthetic arthroplastyIndian J Orthop20074121348

7 

M Szendröi Giant-cell tumour of boneJ Bone Joint Surg2004861512

8 

PJ Mcgrath Giant-cell tumour of bone: an analysis of fifty-two casesJ Bone Joint Surg197254221629

9 

AF Kamal EL Simbolon Y Prabowo EU Hutagalung Wide resection versus curettage with adjuvant therapy for giant cell tumour of boneJ Orthop Surg (Hong Kong)201624222831

10 

AF Kamal A Muhamad Outcomes of En bloc resection followed by reconstruction of giant cell tumor around knee and distal radius. A case seriesAnn Med Surg (Lond)202049616

11 

H Li J Gao Y Gao N Lin M Zheng Z Ye Denosumab in Giant Cell Tumor of Bone: Current Status and PitfallsFront Oncol202010580605

12 

L Xu X Li Z Wang J Xiong S Wang Functional evaluation for patients with lower extremity sarcoma: application of the Chinese version of Musculoskeletal Tumor Society scoring systemHealth Qual Life Outcomes20171516

13 

SA Khan A Kumar P Inna S Bakhshi S Rastogi Endoprosthetic replacement for giant cell tumour of the proximal femurJ Orthop Surg (Hong Kong)20091732803

14 

R Pollock Management of benign bone tumours Orthop Trauma20092324857

15 

R Capanna G Scoccianti F Frenos A Vilardi G Beltrami DA Campanacci What was the survival of megaprostheses in lower limb reconstructions after tumor resections?Clin Orthop Relat Res2015473382030

16 

Y Prabowo DS Ramang S Farqani IW Karda A modified technique of mega prosthesis revision on non-neoplastic patient: Case reportAnn Med Surg (Lond)2020586872

17 

L Selby V Tripathi S Hariharan Knowledge, Attitudes and Practices (KAP) regarding the Novel Coronavirus Disease (COVID-19) Post-lockdown in Trinidad and TobagoSoc Work Public Health202136555876

18 

S Chackan S Islam T Seepaul P Harnarayan V Naraynsingh COVID 19 And Its Impact On Orthopaedic Fracture Surgery And Traumatology In An Eastern Caribbean Island-A RetrospectiveBritish Journal of Medical & Health Sciences (BJMHS)202135

19 

A Haleem M Javaid R Vaishya A Vaish Effects of COVID-19 pandemic in the field of orthopaedicsJ Clin Orthop Trauma20201134989

20 

A Parmeggiani M Miceli C Errani G Facchini State of the art and new concepts in giant cell tumor of bone: imaging features and tumor characteristicsCancers (Basel)202113246298



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.